Breast Cancer

Breast cancer experts address frequently asked questions on adjuvant and metastatic CDK4/6 inhibitor selection in HR-positive breast cancer.

The 510(k) clearance covers an MRI-derived AI risk score for stage I to IIIA disease; the high-risk category carried an HR of 2.81 for recurrence.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.

Nunnery and Bond discuss how patients and advocates can navigate second opinions, mental health support, and the long-term effects of cancer treatment.

Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.

Matthew P. Goetz, MD, explores menopausal status, recurrence risk, and adjuvant CDK4/6 inhibitor selection in HR-positive breast cancer.

Matthew P. Goetz, MD, explores first-line treatment selection, emerging targeted therapies, and unmet sequencing needs in metastatic breast cancer.

Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.

The top 5 OncLive TV videos of the week.

The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

China's approval of Dato-DXd for TNBC was supported by TROPION-Breast02 data showing a median OS of 23.7 months vs 18.7 months with chemotherapy.

Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.

The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.

The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.

Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.

Denosumab-adet (Degevma) is FDA-approved as an Xgeva biosimilar for SRE prevention in myeloma and bone metastases, giant cell tumor of bone, and hypercalcemia of malignancy.

Researchers at Wake Forest University School of Medicine identified a protein that may help breast cancer spread to the brain and evade immune defenses.

The sNDA for elinzanetant seeks FDA approval for moderate to severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.

The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.

Clinicians and researchers are set to gather for the UCSF-cosponsored International Invasive Lobular Carcinoma Symposium.

Read a refresh of breast cancer FDA news from August 2026, including an sNDA application in PIK3CA-mutant disease and a fast track designation.